The EMCDDA–Europol Joint Report on new psychoactive substance MDPV (3,4-methylenedioxypyrovalerone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the EMCDDA and Europol concluded that sufficient information had been accumulated to merit the production of a Joint Report on MDPV as stipulated by Article 5.1 of the Decision.